HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited has published promising Phase III trial results of its drug sovleplenib, showing a notable durable response rate for treating primary immune thrombocytopenia (ITP), a bleeding disorder. The findings, featured in The Lancet Haematology, indicate sovleplenib’s potential as an effective treatment with a good safety profile. Following the success of the ESLIM-01 study, China’s NMPA has accepted the drug for a priority review.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
